会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • VITAMIN D3 ANALOG LOADED POLYMER FORMULATIONS FOR CANCER AND NEURODEGENERATIVE DISORDERS
    • VITAMIN D3模拟装载聚合物制剂用于癌症和神经损伤性疾病
    • US20080260834A1
    • 2008-10-23
    • US12165036
    • 2008-06-30
    • Martin BurkeMaria-Christina WhiteMark C. WattsJae Kyoo LeeBetty M. TylerGary H. PosnerHenry Brem
    • Martin BurkeMaria-Christina WhiteMark C. WattsJae Kyoo LeeBetty M. TylerGary H. PosnerHenry Brem
    • A61K31/59A61K9/10A61P35/00A61P25/28
    • A61K9/0024A61K9/0085A61K9/1641
    • Localized delivery of 1,25 D3 directly to a target area using biodegradable polymeric matrices maximizes the efficacy of this drug while minimizing systemic exposure and toxicity. Anticalcemic analogs of 1,25 D3 have also been incorporated into controlled release polymer formulations to achieve efficacious intracranial concentrations of 1,25 D3 analogs for the treatment of intracranial tumors as well as neurodegenerative disorders such as Alzheimer's disease as well as to maximize the efficacy of these analogs in the treatment of systemic malignancies. The therapeutic efficacy of these formulations was demonstrated through a variety of studies in vitro and in vivo. Hybrid analogs of 1,25 D3 were incorporated into biodegradable polymer wafers composed of a polyanhydride copolymer of 1,3-bis(p-carboxyphenoxy)propane (CPP) and sebacic acid (SA) in a 20:80 molar ratio. In addition to providing improved treatments for malignancies and neurodegenerative disorders, the spatial localization and high reproducibility of this controlled delivery methodology presents a unique opportunity to study in vivo the poorly understood mechanisms of 1,25 D3's antiangiogenic, antiproliferative, and transcriptional regulating activities.
    • 使用可生物降解的聚合物基质直接向目标区域局部递送1,25 D 3 N使该药物的功效最大化,同时使全身暴露和毒性最小化。 1,25 D 3 N的类似物也被并入控释聚合物制剂中,以实现颅内肿瘤治疗的有效颅内浓度1,25D 3 N 3类似物 以及神经变性疾病如阿尔茨海默病,以及使这些类似物在治疗全身性恶性肿瘤中的功效最大化。 通过体外和体内的各种研究证实了这些制剂的治疗功效。 将1,25 D 3 N的混合类似物掺入到由20重量份的1,3-双(对羧基苯氧基)丙烷(CPP)和癸二酸(SA)的聚酐共聚物组成的可生物降解的聚合物晶片中 :80摩尔比。 除了为恶性肿瘤和神经变性疾病提供改进的治疗之外,这种受控递送方法的空间定位和高重现性提供了一个独特的机会,可以在体内研究一个不太了解的1,25 D 3 抗血管生成,抗增殖和转录调节活性。
    • 9. 发明授权
    • Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers
    • 口服活性,抗疟药,抗癌,青蒿素衍生的三恶烷二聚体
    • US07417156B2
    • 2008-08-26
    • US10529513
    • 2003-09-26
    • Gary H. PosnerTheresa A. ShapiroSurojit SurTanzina LabonteKristina BorstnikIk-Hyeon PaikAndrew J. McRiner
    • Gary H. PosnerTheresa A. ShapiroSurojit SurTanzina LabonteKristina BorstnikIk-Hyeon PaikAndrew J. McRiner
    • A61K31/357C07D321/10
    • C07D493/18
    • In only two steps and in 65% overall yield, natural trioxane artemisinin (I) was converted on gram scale into C-10-carba trioxane dimer (3). This new, very stable dimer was then transformed easily in one additional step into four different dimers (4-7). Alcohol and diol dimers (4 and 5) and ketone dimer (7) are 10 times more antimalarially potent in vitro than artemisinin (I), and alcohol and diol dimers (4 and 5) are strongly inhibitory but not cytotoxic toward several human cancer cell lines. Water-soluble carboxylic acid derivatives (8a-10c and 12) were easily prepared from dimers (4-6); they are thermally stable even at 60° C. for 24 hours, are more orally efficacious as antimalarials than either artelinic acid or sodium artesunate, and have potent and selective anticancer activities. Further derivitization of the alcohol dimers (4 and 17), diol dimer (5) and ketone (7) has produced a number of analogs also antimalarially active in vitro at sub-nanomolar concentrations (most notably: pyridine N-oxides (13, 15, 18, 23, 24 and 25), phosphoric acid triesters (26 and 27), sulfonamide (40) and cyclic carbonate (41)). In addition, dimers (13 and 19) are more efficacious (when administered both orally and i.v.) and less toxic (when administered intraperitoneally to mice as a single dose) than clinically-used sodium artesunate, thereby giving them a better antimalarial therapeutic index than sodium artesunate.
    • 只有两个步骤,65%的总产率,将天然的三恶烷青蒿素(I)按克标度转化为C-10-碳三三烷二聚物(3)。 然后将这种新的非常稳定的二聚体在一个额外的步骤中容易地转化成四种不同的二聚体(4-7)。 醇和二醇二聚体(4和5)和酮二聚体(7)在体外比青蒿素(I)具有10倍的抗疟药效力,醇和二醇二聚体(4和5)是强烈抑制的,但对几种人类癌细胞没有细胞毒性 线条。 水溶性羧酸衍生物(8a-10c和12)容易由二聚体(4-6)制备; 它们甚至在60℃下热稳定24小时,作为抗疟药物比阿特金酸或青蒿琥酯钠更具口服效力,并且具有有效和选择性的抗癌活性。 醇二聚体(4和17),二醇二聚物(5)和酮(7)的进一步衍生产生了许多在亚纳摩尔浓度下体外抗疟活性的类似物(最引人注目的是:吡啶N-氧化物(13,15 ,18,23,24和25),磷酸三酯(26和27),磺酰胺(40)和环状碳酸酯(41))。 此外,二聚体(13和19)比临床使用的青蒿琥酯钠更有效(当口服和静脉内施用)和毒性较小(当以单剂量腹膜内给予小鼠时),从而给予它们更好的抗疟治疗指数 青蒿琥酯钠。